Taltz ® (ixekizumab) injection

80 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

TALTZ® (ixekizumab): Doses Greater than 80 mg

Neither efficacy nor safety has been adequately studied for dosage greater than that described in the prescribing information.

Approved Dosing

Psoriasis

Ixekizumab is administered by SC injection. The recommended dose is

  • 160 mg (two 80-mg injections) at week 0

  • 80 mg at weeks 2, 4, 6, 8, 10, and 12, then

  • 80 mg Q4W.1

Psoriatic Arthritis

Ixekizumab is administered by SC injection. The recommended dose is

  • 160 mg (two 80-mg injections) at week 0, then

  • 80 mg Q4W.1

For patients with PsA and coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis.1

Axial Spondyloarthritis

Ixekizumab may be administered alone or in combination with a cDMARD (eg, MTX).1

Radiographic Axial Spondyloarthritis/Ankylosing Spondylitis

Ixekizumab is administered by SC injection. The recommended dose is

  • 160 mg (two 80-mg injections) at week 0, then

  • 80 mg Q4W.1

Nonradiographic Axial Spondyloarthritis

Ixekizumab is administered by SC injection. The recommended dose is 80 mg Q4W.1

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

Reference

1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Glossary

cDMARD = conventional disease-modifying antirheumatic drug

MTX = methotrexate

PsA = psoriatic arthritis

Q4W = every 4 weeks

SC = subcutaneous

Date of Last Review: October 22, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical